15 Jul Rader, Janet S., MD
Dr. Janet S. Rader became the Jack A. & Elaine D. Klieger Professor and Chair of the Department of Obstetrics and Gynecology at the Medical College of Wisconsin in September, 2009. She received her Doctor of Medicine degree from the University of Missouri. She completed her residency in Obstetrics and Gynecology at Michael Reese Hospital and Medical Center. She did a Fellowship in Gynecologic Oncology at the Johns Hopkins University Hospital. She is board certified in obstetrics and gynecology and gynecologic oncology.
Named in U.S. News & World Report’s Top Doctors List for 2012-2013, Dr. Rader is ranked in the top 1% of Gynecologic Oncologists nationwide. Dr. Rader’s practice involves chemotherapy and surgery (including laparoscopic/robotic procedures). She specializes in cervical, ovarian and uterine cancers, gestational trophoblastic disease, pelvic masses, cancer screening and prevention.
In addition to leading the department, Dr. Rader provides leadership in development of a Women’s Health Research Program and while continuing her own research program in gynecologic cancers.
She has received National Institutes of Health (NIH) and American Cancer Society (ACS) funding for her research since 1994. Her research focus is on early molecular changes and genetic predisposition for cervical cancer.
Her laboratory focuses on identifying genes involved in the progression of cervical cancer through the analysis of molecular changes in the preinvasive and invasisve neoplasias of the cervix, in addition to identifying host genetic susceptibility polymorphisms in the progression of disease.
Dr. Rader has 149 peer reviewed publications and 24 book chapters.
In her spare time, she enjoys yoga, long walks and bike riding. She is an avid spectator at her son’s sporting events.
At a Glance
Areas of Expertise
- Cervical Cancer
- Gestational Trophoblastic Disease
- Minimally Invasive Surgery
- Gynecologic Cancers
- Pelvic Masses
- Vulvar and Vaginal Cancers
- Cancer Screening and Prevention
- Ovarian Cancer
- Endometrial Cancer
- Second Opinions
- Chemotherapy for Treatment of Gynecologic Cancers
- Intraperitoneal Chemotherapy
- Cancer Treatment
- Obstetrics and Gynecology
- Gynecologic Oncology
Patient Ages Seen
- Infant (0-12 months)
- Child (1-12 yrs)
- Adolescent (13-18 yrs)
- Adult (18 + )
- Senior (60 +)
Education / Training
- Doctor of Medicine – University of Missouri, St. Louis (1983)
- Internship in Obstetrics & Gynecology – Michael Reese Hospital and Medical Center – Chicago, IL (1983-1984)
- Residency in Obstetrics & Gynecology – Michael Reese Hospital and Medical Center – Chicago, IL (1984-1987)
- Fellowship in Gynecologic Oncology – Johns Hopkins University Hospital – Baltimore, MD (1995-1998)
MCW Start Date
|Principal Investigator||Title of Research Study
Awards / Publications / Presentations
|Rader, Janet S., MD, FACOG and Kaljo, Kristina, PhD||Student-Centered Pipeline to Advance Research in Cancer Careers (SPARCC) for Underrepresented Minority Students
*Grant funded by NIH Cancer Institute
|Rader, Janet S., MD, FACOG||TCGA Database Project|
|Rader, Janet S., MD, FACOG||MAP3: 125-04 A Phase III Randomized Study of Exemestane Plus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer|
|Rader, Janet S., MD, FACOG||"HPV Assays for GOG 207: HPV Assays for GOG 207 (A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3) (IND #69,656, Sponsor – GOG)"|
|Rader, Janet S., MD, FACOG||"TCGA Cervical: RECOVERY - The Cancer Genome Atlas Project - Cervical Cancer"|
|Rader, Janet S., MD, FACOG||"CerGE-Genetic Susceptibility: Genetic Susceptibility to Cervical Cancer (Cervical Cancer Genetic Epidemiology)"|
|Rader, Janet S., MD, FACOG||"The Role of Slit-Robo Pathway in Gynecological Cancer Progression"|
|Rader, Janet S., MD, FACOG||"Role of Microenvironment in Gynecological Tumor Metastasis"|
|Uyar, Denise S., MD, Bishop, Erin, MD, Bradley, William, MD, Rader, Janet, MD, Precious Akinsanya||Preliminary Data on First Line Combination Carboplatin, Taxane and Pembrolizumab Therapy Followed by Maintenance Pembrolizumab for Cytoreduced Ovarian Cancer with Residual Disease
* Presented at Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, March 24-27, 2018
In the News
Dr. Rader is a very attentive listener and provides adequate time for thorough communication between patient and staff. She is top notch in her attention to detail and concern for the patient as well as finding the best treatment for each individual. I highly recommend her.
I just wish all doctors were as wonderful as Dr. Janet Rader. If I had a friend or a family member that had cancer, I would not let them go to anyone except her.
All were pleasant. Consider myself fortunate to be a patient of Dr. Rader.
Dr. Janet Rader is Phenomenal! We are so lucky to have her. Not only did she save my life, but she did it in the least obtrusive manner possible. Even in our first meeting, I felt a connection with her. She is a strong, positive force and I wanted her fighting for me. I will be forever in her debt.